成都康弘药业集团股份有限公司 关于公司收到药物临床试验批准通知书的公告

Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd. has received the clinical trial approval notice from the National Medical Products Administration for its drug KHN707, which is aimed at treating insomnia [1][2]. Group 1: Drug Information - Drug Name: KHN707 Tablets - Dosage Form: Tablet - Indication: Insomnia - Registration Classification: Class 1 Chemical Drug - Acceptance Numbers: CXHL2501386, CXHL2501387 - Approval Conclusion: Clinical trials for insomnia treatment are approved [1]. Group 2: Product Overview - KHN707 is a selective orexin receptor 2 (OX2R) antagonist, classified as an innovative Class 1 chemical drug. - Preliminary research indicates that KHN707 has good safety and effective therapeutic effects in insomnia models, suggesting a promising clinical application outlook [1]. Group 3: Impact on the Company - The uncertainty surrounding the drug's development, clinical trials, review, and approval processes necessitates cautious decision-making by investors [2].